---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-025576"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:33:06.939036+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Veru reports Q1 net loss $8.9M; positive Phase 2b enobosarm data; FC2 business sold for $18M

## Summary
- Net loss from continuing ops $1.8M ($0.01/sh) vs $7.7M; overall net loss $8.9M ($0.06/sh) vs $8.3M.
- R&D expenses rose to $5.7M from $1.7M; SG&A fell to $5.2M from $6.7M; cash $26.6M at Dec 31, 2024.
- Phase 2b QUALITY study met primary endpoint: 71% relative reduction in lean mass loss (p=0.002) with enobosarm+semaglutide.
- Enobosarm 3mg+semaglutide preserved 99% of lean mass; 62% relative reduction in stair climb power decline (p=0.0066).
- Sold FC2 Female Condom business for $18M; net proceeds ~$12.3M; $9.9M liability extinguished.

## SEC filing metadata
- accession: 0001193125-25-025576
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312525025576/0001193125-25-025576-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312525025576/d935703d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-025576
- JSON: https://secwatch.observer/filing/0001193125-25-025576.json
- Plain text: https://secwatch.observer/filing/0001193125-25-025576.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.